Journal article

New insulin analogues and perioperative care of patients with type 1 diabetes

J Killen, K Tonks, J Greenfield, DA Story

ANAESTHESIA AND INTENSIVE CARE | AUSTRALIAN SOC ANAESTHETISTS | Published : 2010

Abstract

While insulin remains the mainstay of managing type 1 diabetes, much has changed over the last 15 years. These changes should help in managing patients with type 1 diabetes during the perioperative period. More flexible insulin therapy has three components: (1) basal, (2) prandial and (3) corrective. Many patients, particularly younger patients, are using genetically modified recombinant human insulin analogues. Two of these analogues, aspart and lispro insulin, are rapid-acting with faster onset and offset than subcutaneous regular insulin, allowing both prandial and corrective boluses. Other insulin analogues, particularly glargine and possibly detemir have a flat profile of up to 24 hours..

View full abstract

University of Melbourne Researchers